News

J&J posts mid-stage trial data for chemotherapy releasing system in bladder cancer
Johnson & Johnson (JNJ) posts promising Phase 2b trial results for its chemotherapy releasing system TAR-200 in bladder ...
CURE10d
FDA sBLA Submitted for Anktiva Plus BCG in Papillary Bladder Cancer
A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.
Nasdaq6d
Johnson & Johnson unveils highly anticipated and potential practice-changing data in bladder cancer treatment at AUA
Compelling first results from Cohort 4 of Phase 2b SunRISe-1 study show potential of TAR-200 monotherapy in patients with papillary-only, high-risk non-muscle invasive bladder cancer Bladder ...
Seeking Alpha6d
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
in non-muscle invasive bladder cancer carcinoma in situ (NMIBC CIS) and updated data on papillary disease without CIS at the American Urological Association Annual Meeting (AUA 2025) in Las Vegas ...
Yahoo Finance6d
ImmunityBio to Showcase Advances for Bladder and Prostate Cancer at American Urological Association (AUA) Annual Meeting
With or Without Ta/T1 Papillary Disease (PD12-12) Chang S. Oral Podium Presentation. Session: Bladder Cancer: Non-Invasive II, Saturday, April 26, 3:30 pm - 5:30 pm PDT, Galileo 1001, The Venetian ...